IDEAYA Biosciences, Inc.
IDYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | -0.48 | -18.10 | -2.19 |
| FCF Yield | -11.98% | -5.75% | -12.03% | -7.01% |
| EV / EBITDA | -7.52 | -17.37 | -12.16 | -15.54 |
| Quality | ||||
| ROIC | -30.32% | -21.54% | -17.45% | -14.88% |
| Gross Margin | 45.23% | 82.86% | 95.87% | 93.83% |
| Cash Conversion Ratio | 0.90 | 1.02 | 1.49 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -48.39% | -5.76% | 37.63% | 3,034,354.63% |
| Free Cash Flow Growth | -113.82% | -29.77% | -55.11% | -206.28% |
| Safety | ||||
| Net Debt / EBITDA | 0.24 | 1.41 | 1.15 | 1.81 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,467.94 | -600.58 | -742.04 | -429.94 |